Announcement on Correction of Report for Q3 2024
Filed with SSE · · 2 pages · Chinese
Jenkem Technology Co., Ltd. on 6ix
Earlier from Jenkem Technology
- Announcement on Closing Some Investment Projects Financed by Raised Funds and Using Residual Raised Funds to Permanently Supplement Current Capital
- Announcement on Voluntary Disclosure of the First Subject Being Enrolled in Phase III Clinical Trial of Polyethylene Glycol Irinotecan for Treatment of Small Cell Lung Cancer
- Announcement Published in a Journal Regarding Voluntary Disclosure of Phase II Study on the Safety, Tolerability and Preliminary Efficacy of Polyethylene Glycol Irinotecan as Second-Line Monotherapy for Small Cell Lung Cancer
- Announcement on Meeting the Vesting Conditions in the 2nd Vesting Period of Those Reserved for Grant in the 2021 Restricted Stock Incentive Plan
Later from Jenkem Technology
- Announcement on Resolution of the 11th Meeting of the 3rd Board of Directors
- Announcement on Voluntary Disclosure of the First Subject Being Enrolled in Phase II Clinical Trial of Pegylated Irinotecan in Treating Triple Negative Breast Cancer with Brain Metastasis
- Announcement on the Vesting Results of the 2nd Vesting Period of the Part Reserved for Grant under the 2021 Restricted Stock Incentive Plan and Listing of Shares
- Announcement on Change of Employee Representative Supervisor and Chairman of the Board of Supervisors
- Annual Earnings Preannouncement for 2024
Follow Jenkem Technology into a list and get an email when it puts out news.
Follow Jenkem Technology